ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Letermovir For The Treatment And Secondary Prophylaxis Of Drug Resistant CMV In Solid Organ Transplant Recipients

M. R. Pereira1, J. G. Aaron1, C. J. Kubin2

1Medicine - Infectious Diseases, Columbia University Medical Center, New York, NY, 2Medicine - Infectious Diseases, NewYork Presbyterian Hospital, New York, NY

Meeting: 2019 American Transplant Congress

Abstract number: 333

Keywords: Cytomeglovirus, Ganciclovir, Infection, Outcome

Session Information

Session Name: Concurrent Session: Breakthroughs in Cytomegalovirus

Session Type: Concurrent Session

Date: Monday, June 3, 2019

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:06pm-5:18pm

Location: Ballroom A

*Purpose: Although only approved for primary prophylaxis of CMV among allogeneic stem cell transplant recipients, there is great interest in the use of letermovir (LET) among solid organ transplant (SOT) recipients with drug resistant CMV due to toxicity of alternative agents and novel mechanism of action. We sought to describe our experience with LET for SOT recipients.

*Methods: All adult SOT recipients with of drug resistant CMV who received LET in 2018 for treatment or secondary prophylaxis were evaluated. Patient and CMV characteristics as well as outcomes were obtained.

*Results: Nine SOT recipients received LET for drug resistant CMV. Five received LET 720 mg daily for treatment of active infection and four received LET 480 mg daily for secondary prophylaxis. At both doses, LET was well tolerated and without significant bone marrow suppression, hepatotoxicity or nephrotoxicity. Among the patients on treatment dose, two achieved undetectable CMV PCR (<35 IU/mL) and two achieved a reduction in CMV PCR to a persistently low level (< 500 IU/mL). One patient (C) had ganciclovir added at 21 days. No patients developed new or worsening tissue invasive disease after LET was initiated. One recipient on secondary prophylaxis experienced breakthrough viremia during week 2.

*Conclusions: LET for treatment or secondary prophylaxis among SOT recipients appears to be safe and possibly effective in this ongoing cohort study. Given the urgent need for well tolerated effective treatment for resistant CMV in SOT recipients, LET and combination therapies should be studied.

Patient and CMV characteristics in the treatment dose (720 mg daily) cohort
Patient Demographics Organ transplanted CMV presentation Prior treatments Resistance mutations
A 45 y.o. man Heart Syndrome GCV UL54 D413E/V812L
B 76 y.o. man Lung Syndrome GCV, FOS, CMV-IgG UL54 N408D, UL97 M460I
C 70 y.o. man Lung Syndrome, colitis GCV, FOS UL54 T503I, UL97 C603W
D 49 y.o. man Kidney Syndrome GCV, FOS, Maribavir UL97 C592G
E 30 y.o. woman Lung Syndrome, GI GCV UL97 L595S

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Pereira MR, Aaron JG, Kubin CJ. Letermovir For The Treatment And Secondary Prophylaxis Of Drug Resistant CMV In Solid Organ Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/letermovir-for-the-treatment-and-secondary-prophylaxis-of-drug-resistant-cmv-in-solid-organ-transplant-recipients/. Accessed June 1, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences